We recently demonstrated a marked inhibitory effect of high physiological concentrations of free fatty acids (FFAs) on insulin binding, degradation, and action in isolated rat hepatocytes. To elucidate the mechanism, male rats were treated for 3 days with saline (control) or etomoxir (ethyl 2-[6-(p-chlorophenoxy)hexyl]-glycidate), a prodrug, which in vivo is converted to a specific competitive inhibitor of carnitine palmitoyltransferase, and thus, lipid oxidation. Oleic acid (0.4 mM) reduced both O bese subjects with an abdominal fat distribution are, for a given degree of obesity, more insulin resistant than equally obese individuals with a gluteofemoral fat distribution (1-4). Furthermore, they are more prone to develop diabetes and cardiovascular disease (5,6). The reason for this difference is unclear but has been attributed to the adipose tissue, particularly an increased free-fatty acid (FFA) release (1, 3, 4) .
O bese subjects with an abdominal fat distribution are, for a given degree of obesity, more insulin resistant than equally obese individuals with a gluteofemoral fat distribution (1) (2) (3) (4) . Furthermore, they are more prone to develop diabetes and cardiovascular disease (5, 6) . The reason for this difference is unclear but has been attributed to the adipose tissue, particularly an increased free-fatty acid (FFA) release (1, 3, 4) .
Both abdominal subcutaneous (7) and intra-abdominal fat cells (8) are more responsive to lipolytic hormones than fat cells from the gluteofemoral region. These in vitro findings are paralleled by an increased FFA turnover in abdominal obesity (9) . Furthermore, increased lipolysis in an expanded intra-abdominal depot leads to an increased flow of glycerol and FFAs to the liver via the portal vein. Diet-induced obesity in experimental animals is associated with a decreased insulin clearance by the liver (10) . The potential importance of this mechanism for the more pronounced hyperinsulinemia in abdominal obesity is shown by the observation that hepatic insulin uptake is reduced in these subjects (11, 12) .
We recently reported that high physiological concentrations of FFAs markedly reduced insulin binding, degradation, and action in isolated rat hepatocytes (13) . To elucidate the mechanism by which FFAs inhibit insulin action, we investigated FFA effect on insulin binding in isolated hepatocytes from rats treated with etomoxir, a lipid oxidation inhibitor (14) shown to lower plasma glucose in rats with experimental diabetes (15). The data show that etomoxir treatment effectively prevents the inhibitory effect of elevated FFAs on insulin binding and action.
RESEARCH DESIGN AND METHODS
Male Sprague-Dawley rats (Alab, Stockholm, Sweden) weighing -2 0 0 g were used for all experiments. The animals were kept at a constant temperature and had free access to laboratory chow (22.5% protein, 72.5% carbohydrate, 5% fat, and sufficient vitamins and minerals) throughout the experiments. All studies were performed with the rats in the fed state. Isotonic saline or etomoxir (ethyl 2-[6-(pchlorophenoxy)hexyl]glycidate; 50 mg/kg body wt i.p.; BykGulden, Konstanz, Germany) was administered at 0900 for 3 days.
On the 4th day, hepatocytes were isolated according to the method originally described by Seglen (16) with the modifications recently described (13) . Briefly, after induction of general anesthesia, the liver was perfused through a portal cannula with calcium-free Krebs-Ringer bicarbonate-HEPES buffer (KRBH) containing 5.5 mM glucose and 2 mM EDTA (pH 7.4) followed by KRBH containing 5.5 mM glucose and 0.05% collagenase (Sigma, St. Louis, MO) for 5 min. The cells were washed in fresh medium and the hepatocytes separated from the nonhepatocytes by centrifugation at 50 x g for 1 min.
After washing the cells four times in fresh medium, insulin binding was carried out essentially as described by Gammeltoft et al. (17) . A14-Tyrl25 l-labeled insulin (sp act 220 |xCi/|xg, Novo, Copenhagen) at a final concentration of 200 pM was added together with increasing concentrations of unlabeled insulin to isolated hepatocytes (cell concn -1 0 5 cells/ml). The incubations were performed for 45 min at 37°C in a final volume of 1 ml. To separate the bound from the unbound insulin, the cells were centrifuged through dibutyl phthalate oil in Eppendorf microfuge tubes (13) . No unbound radioactive material passed through the oil layer. [ 14 C]aminoisobutyric acid (AIB; sp act 50 mCi/mmol; Du Pont-NEN, Boston, MA) uptake was studied with some modifications of the method described by Svedberg et al. (13) and Fehlman et al. (18) . After preincubation in the absence or presence of different concentrations of insulin for 30 min, 0.68 |xM [ In some experiments, hepatocytes were solubilized with Triton X-100 and the solubilized insulin receptors partially purified on wheat-germ agarose columns as described earlier (13) . Insulin binding to solubilized receptors was carried out at 4°C for 20 h and the bound hormone separated from free hormone by precipitation with polyethylene glycol as described previously (13) .
Statistical significance was evaluated with Student's t test for paired or unpaired data as appropriate.
RESULTS
Etomoxir treatment did not change the size or the viability (>90%) of the hepatocytes as assessed with trypan blue exclusion (data not shown). Neither insulin binding nor AIB uptake was changed by preincubating the cells for 30 min in vitro with etomoxir (0.05-50 mg/ml). Furthermore, the inhibitory effect of 0.4 mM oleic acid was not influenced under these conditions (data not shown). Figure 1/4 shows the inhibitory effect of 0.4 mM oleic acid on specific insulin binding to the isolated hepatocytes. At this concentration, oleic acid reduced the cell-associated insulin binding by -40%. The apparent mean ± SE K d was 1.03 ± 0.05 (n = 5) and 1.03 ± 0.03 nM in control cells and cells exposed to oleic acid, respectively, indicating that the receptor affinity was not affected by FFA. This was further validated by analyzing the data according to Scatchard (19; Fig. A A, inset) . Figure 18 shows the effect of 0.4 mM oleic acid on insulin binding to isolated hepatocytes from etomoxir-treated rats. In this study, oleic acid did not exert any effect on insulin binding. Total binding to cells from etomoxir-treated animals was also similar to that in control cells. The receptor affinity was also unchanged with an apparent K 6 of 1.05 ± 0.03 nM in untreated cells and cells exposed to oleic acid (Fig. 16,  inset) . Furthermore, binding to partially purified receptors from solubilized cells was not changed by etomoxir (data not shown).
The dose-response curve for the inhibitory effect of oleic acid on 125 l-insulin binding is shown in Fig. 2 . The data demonstrate that the maximal inhibitory effect of 53 ± 11% was exerted at 1.2 mM and half-maximal effect at 0.14 ± 0.06 mM. However, in cells from etomoxir-treated animals, the inhibitory effect of oleic acid at 1.2 mM was 26 ± 12%, and the half-maximal effect was seen at 0.35 ± 0.03 mM. (Fig. 3) . In the presence of 0.4 mM oleic acid, AIB uptake in the absence of insulin was significantly reduced by 39 ± 8% (P < 0.01). The maximal insulin effect was also reduced by -40%. Thus, a proper estimation of ED 50 for insulin could not be calculated with this small response. In cells from etomoxir-treated rats, AIB uptake in the absence of insulin was 0.92 ± 0.24 nmol/10 5 cells. A high concentration of insulin increased AIB uptake -50%. Addition of oleic acid did not significantly change either basal or insulin-stimulated uptake in these cells (Fig. 3) .
DISCUSSION
We recently showed that high physiological FFA concentrations are capable of rapidly inhibiting insulin binding, deg- radation, and action in isolated hepatocytes through an energy-requiring process (13) . This effect is due to a decrease in the number of available binding sites. However, total binding to partially purified receptors from solubilized cells is not changed by FFAs (13) . This study shows that etomoxir, a specific and competitive inhibitor of carnitine palmitoyltransferase 1, the enzyme reponsible for mitochon- drial fatty acid transport and subsequent oxidation, prevents the inhibitory effects of FFA.
Because etomoxir is basically an FFA analogue, it cannot be completely excluded that it may become incorporated into the plasma membrane and exert a local effect. Our previous data, demonstrating that the FFA effect is rapid, energy dependent, and not seen on isolated receptors from solubilized cells, do not support this possibility (13) . Furthermore, hepatocytes from animals treated with etomoxir bound and responded to insulin to essentially the same extent as cells from control rats, indicating that etomoxir does not directly influence insulin binding and metabolism in isolated hepatocytes from these nonobese animals. This is also supported by the finding that etomoxir added directly to the cells in vitro was without effect. In conclusion, it seems that etomoxir in this study elicits its influence by inhibiting the FFA effect. Together, these data strongly indicate that the effect of FFAs on insulin binding and action is linked to their metabolism and oxidation.
The finding that FFAs may affect insulin uptake and action in hepatocytes indicates that the ambient FFA level may play an important role as a physiological regulator of insulin sensitivity and response in the liver. The insulin effect on the liver would be diminished under conditions of high FFA levels, which among other things could lead to a relative increase in hepatic glucose production. In fact, FFA infusion in humans has been shown to reduce the hepatic sensitivity to insulin (20) . Furthermore, gluconeogenesis is elevated in different conditions associated with high FFA levels, such as diabetes and obesity (21) .
Animal experiments suggest that ambient FFA levels may exert an important regulatory effect on insulin handling by the liver. Hepatic insulin uptake is inversely proportional to the hepatic triglyceride concentration in the in situ perfused rat liver (10) . High portal FFA levels have also been reported to reduce insulin clearance in this system (22) . Together, these data demonstrate a new potential mechanism for the link between elevated FFA levels, insulin resistance, and diabetes.
